FMP
Turnstone Biologics Corp.
TSBX
NASDAQ
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
0.34 USD
-0.0101 (-2.97%)
Historical Prices
From:
To:
About
ceo
Dr. Sammy J. Farah M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://turnstonebio.comexchange
NASDAQ
Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
CIK
0001764974
ISIN
US90042W1009
CUSIP
90042W100
Address
9310 Athena Circle
Phone
347-897-5988
Country
US
Employee
14
IPO Date
Jul 21, 2023
Financial Statement
Earnings
TSBX Financial Summary
CIK
0001764974
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
90042W100
ISIN
US90042W1009
Country
US
Price
0.34
Beta
1.3
Volume Avg.
125.86k
Market Cap
7.86M
Shares
-
52-Week
0.29-3.259
DCF
1.2
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.11
P/B
-
Website
https://turnstonebio.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TSBX News
Gordon Thompson
Nov 10, 2024
Turnstone Biologics Corp. (NASDAQ: TSBX) Faces Challenges De...
Turnstone Biologics Corp. (NASDAQ: TSBX) is a biotechnology company dedicated to developing treatments for solid tumors. Their main product, TIDAL-01, is in Phase 1 clinical trials for breast cancer, colorectal cancer, and uveal melanoma. They are also working on TIDAL-02, which is in preclinical development for solid tumors. The company operates in a competitive field, with other biotech firms also targeting cancer treatments. Despite the promising pipeline, TSBX's stock price has seen a signi...
InvestorPlace
Aug 15, 2024
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents.
24/7 Wall Street
Aug 8, 2024
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
GlobeNewsWire
May 8, 2024
Turnstone Biologics to Present at the 2024 Bank of America S...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May ...
GlobeNewsWire
Feb 21, 2024
Turnstone Biologics to Participate in Upcoming Investor Conf...
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44 th Annual Global Health Care Conference Type: ...
GlobeNewsWire
Sep 28, 2023
Turnstone Biologics to Present Preclinical Data for Selected...
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone's Selected TIL therapies will be presented at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
GuruFocus
Jul 27, 2023
FMR LLC Acquires Significant Stake in Turnstone Biologics Co...
On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Financial). This article provides an in-depth analysis of the transaction, profiles of both FMR LLC (Trades, Portfolio) and Turnstone Biologics Corp, and the potential implications of this acquisition on the market.
Market Watch
Jul 21, 2023
Turnstone Biologics set to go public as upsized $80 million ...
Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said it sold 6.67 million shares in the IPO, up from a previously expected offering of 5.80 million shares.
